Use of Mendelian randomisation to assess potential benefit of clinical intervention
Use of Mendelian randomisation to assess potential benefit of clinical intervention
复制标题
DOI：
10.1136/bmj.e7325
复制
发表时间：
2012-11-06
影响因子：
105.7
通讯作者：
Thompson, Simon G.
中科院分区：
文献类型：
--
作者：
Burgess, Stephen;Butterworth, Adam;Thompson, Simon G.
孟德尔随机化是一种评估观察数据中因果关联的技术。与感兴趣的风险因素相关的遗传变异的处理方式与临床试验中的随机分配类似。然而，由遗传变异引起的风险因素的差异与任何拟议的治疗干预引起的变化在本质上是不同的，因此可能会以不同的方式影响结果。因此，将孟德尔随机化估计的大小概括为潜在干预措施对实践中风险因素的影响可能会产生误导。认识到此类估计的局限性对于在基于目标的药物开发中使用孟德尔随机化非常重要
Mendelian randomisation is a technique for assessing causal associations in observational data. Genetic variants associated with the risk factor of interest are regarded in a similar way to random assignment in a clinical trial. The difference in the risk factor due to the genetic variation, however, is materially distinct from the change due to any proposed therapeutic intervention and so might affect the outcome differently. Consequently, it can be misleading to generalise the magnitude of a Mendelian randomisation estimate to the effect of a potential intervention on the risk factor in practice. Awareness of the limitations of such estimates is important for the use of Mendelian randomisation in target based drug development